摘要
目的探讨Ki-67、Her-2及Top2A在乳腺癌中的扩增表达与蒽环类药物疗效的关系。方法 207例经病理证实的乳腺癌患者均接受FEC方案新辅助化疗,并测定其Ki-67、Her-2及Top2A基因的表达。结果207例乳腺癌患者中,Ki-67分级为(-)32例,(+)58例,(++)95例,(+++)22例;Her-2基因扩增26例(12.6%),未扩增181例(87.4%);Top2A基因扩增26例(12.6%),未扩增181例(87.4%)。Ki-67分级与Her-2基因、Top2A基因扩增无关(P>0.05)。Her-2、Top2A的扩增与化疗疗效均呈正相关(r=0.59、0.58,P<0.05)。结论 Her-2、Top2A的表达对乳腺癌患者化疗药物的选择及预后的判断具有重要的指导价值。
Objective To explore the relationship of Ki-67 ,Her-2 and Top2A amplification in the breast cancer and efficacy of anthracycline-based regimen. Methods The 207 patients with breast cancer confirmed by pathology underwent the FCC regimen neoadjuvant chemotherapy, and the Ki-67, Her-2, Top2A gene expressions were detected. Results Among the 207 patients,Ki-67 classification of （ - ） were 32 patients,58 patients were （ ＋ ） ,95 patients were （ ＋＋ ） ,22 patients were （ ＋＋＋ ）. Her-2 gene amplification were 26 patients （ 12.6% ） ,no-amplification were 181 patients （87.4%）. Top2A gene amplification were 26 patients （12.6%） ,no-amplification were 181 patients （ 87.4% ）. Ki-67 classification was unrelated with the amplification of Her-2 and Top2A genes （ P 〉 0. 05 ）. Her-2 and Top2A amplification were positive correlated with the effect of chemotherapy （ r = 0.59,0.58 ; P 〈 0.05 ）. Conclusion The expression of Her-2 and Top2A has important guiding value in the selection of chemotherapy drugs and prognosis of patients with breast cancer.
作者
张成娟
董凤梅
徐本玲
袁鹏
ZHANG Chengjuan DONG Fengmei XU Benling YUAN Peng(Henan Provincial Tumor Hospital, Zhengzhou 450008, China Zhengzhou Central Hospital, Zhengzhou 450007, China)
出处
《肿瘤基础与临床》
2017年第1期11-14,共4页
journal of basic and clinical oncology
基金
国家自然科学基金青年基金资助项目(编号:81602637)
河南省科技攻关计划项目(编号:162102410046)
关键词
KI-67
HER-2
DNA拓扑异构酶Ⅱα
乳腺癌
蒽环类药物
Ki-67
human epidermal growth factor receptor 2
DNA topoisomerase Ⅱ α
breast cancer
augmentation
anthracycline-based drugs
